抗体药物偶联物相关药物性肝损伤研究进展  

Research Progress of Drug-induced Liver Injury of Antibody-drug Conjugate

作　　者：高媛 冉怡雯 吴晶晶 宋再伟 赵荣生[1,2] GAO Yuan;RAN Yiwen;WU Jingjing;SONG Zaiwei;ZHAO Rongsheng(Department of Pharmacy,Peking University Third Hospital,Beijing 100191,China;Institute for Drug Evaluation,Peking University Health Science Center,Bejing 100191,China;Department of Pharmacy Administration&Clinical Pharmacy,School of Pharmaceutical Sciences,Peking University,Beijing 100191,China)

机构地区：[1]北京大学第三医院药剂科,北京100191 [2]北京大学医学部药物评价中心,北京100191 [3]北京大学药学院药事管理与临床药学系,北京100191

出　　处：《药学进展》2023年第2期92-100,共9页Progress in Pharmaceutical Sciences

基　　金：白求恩基金会项目(No.B-19-H-20200622)。

摘　　要：抗体药物偶联物(ADC)通过将细胞毒药物与单克隆抗体偶联实现有效载荷的靶向递送,为恶性肿瘤治疗提供了一种有效治疗手段。随着ADC在全球范围内越来越多地应用于肿瘤治疗,其导致的用药相关不良反应日益受到关注。其中,ADC导致的药物性肝损伤是最常见的不良反应之一,临床治疗过程中应积极关注,并根据肝损伤程度采取相应的管理措施。通过对ADC导致肝损伤不良反应的临床表现、发生率以及发生机制等进行回顾性分析,并对ADC导致肝损伤后的应对处置进行归纳综述,以期为ADC临床合理用药提供参考。Antibody-drug conjugate(ADC),which conjugates cytotoxic drugs and monoclonal antibodies to reach target delivery of a potent payload,is an effective treatment for malignant tumor.ADC has been increasingly used for the treatment of tumors in a global context,but its drug-related adverse reactions have received more and more attention.Drug-induced liver injury(DILI)caused by ADC has become one of the most common adverse reactions,so more attention should be paid to the clinical treatment,in which corresponding measures should be taken on the basis of the degree of hepatic injury.This article is a retrospective analysis of the clinical manifestations,incidence rate and potential mechanism of ADC leading to liver injury,and a review of management after liver injury induced by ADC,aiming to provide reference for rational drug use of ADC in clinic.

关 键 词：恶性肿瘤 抗体药物偶联物 药物性肝损伤 

分 类 号：R575[医药卫生—消化系统] R979.1[医药卫生—内科学]